EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ADAMTS4 is a serum biomarker for pulmonary arterial hypertension associated with congenital heart disease

Genfa Xiao, Yuanrong Chen, Ying Meng, Ziliang Wang, Jiumei Cai, Zuofeng Cao, Shixiu Zeng, Weihua Liang, Yueling Yu, Haobo Wang, Lijun Nie, Xiaoli Liu und 1 weitere

Frontiers in Medicine · 22.07.2026 · 13

DOI: 10.3389/fmed.2026.1863052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Medicine, online erschienen am 22.07.2026. Verfasst von Genfa Xiao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Heart Medical Centre, First Affiliated Hospital of Gannan Medical University, Ganzhou, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) is a cardiopulmonary disorder characterized by pathological pulmonary vascular remodeling and perivascular inflammatory cell infiltration. ADAMTS4 is a secreted, zinc-dependent metalloprotease critically involved in extracellular matrix degradation and turnover and has recently emerged as a potential biomarker in vascular remodeling diseases. This study aimed to evaluate the diagnostic performance and prognostic value of serum ADAMTS4 in patients with PAH-CHD.

Methods

This study included patients with PAH-CHD, patients with CHD, and healthy controls. Serum ADAMTS4 levels were measured by ELISA. Correlations with clinical parameters were assessed using Spearman’s rank correlation. The diagnostic efficacy was evaluated by ROC curve analysis. Univariate and multivariable logistic regression were used to identify independent risk factors associated with the presence of PAH-CHD. PAH-CHD patients were followed up for a median duration of 40.5 months, and Kaplan–Meier and Cox regression analyses were used to analyze prognosis.

Results

Compared with those in CHD patients and healthy controls, serum ADAMTS4 levels were elevated in PAH-CHD patients. ADAMTS4 was positively correlated with NT-proBNP ( r = 0.45, p = 0.002), CRP ( r = 0.60, p < 0.001), and WHO functional class ( r = 0.49, p < 0.001). ROC analysis demonstrated good discriminatory ability for differentiating PAH-CHD from CHD (AUC = 0.78; 95% CI: 0.69–0.87; p < 0.001), with an optimal cutoff value of 42.2 ng/mL. After multivariable adjustment, logistic regression revealed that ADAMTS4 remained an independent factor associated with the presence of PAH-CHD (OR = 1.189; 95% CI: 1.036–1.365; p = 0.014). Kaplan–Meier analysis revealed significantly shorter event-free survival in patients with ≥ 42.2 ng/mL ADAMTS4 than in those with lower levels (log-rank p = 0.046). After multivariable adjustment, Cox regression confirmed ADAMTS4 as an independent predictor of adverse clinical events (HR = 1.038; 95% CI: 1.007–1.071; p = 0.017).

Conclusion

Serum ADAMTS4 is elevated in patients with PAH-CHD and is correlated with disease severity and adverse outcomes. These findings support its utility as a noninvasive serum biomarker for diagnosis, risk stratification and prognostic assessment in PAH-CHD patients.

Schlagwörter

Stichwörter der Autor:innen

ADAMTS4biomarkerdiagnosisprognosispulmonary arterial hypertension associated with congenital heart disease

Autor:innen und Institutionen

  • Department of Cardiology, Heart Medical Centre, First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
  • Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
  • First Clinical Medical College of Gannan Medical University, Ganzhou, China.

Förderung

  • NIA NIH HHS

Zitieren

APA

Xiao, G., Chen, Y., Meng, Y., Wang, Z., Cai, J., Cao, Z., Zeng, S., Liang, W., Yu, Y., Wang, H., Nie, L., Liu, X., & Liao, Y. (2026). ADAMTS4 is a serum biomarker for pulmonary arterial hypertension associated with congenital heart disease. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1863052

Vancouver

Xiao G, Chen Y, Meng Y, Wang Z, Cai J, Cao Z, et al. ADAMTS4 is a serum biomarker for pulmonary arterial hypertension associated with congenital heart disease. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1863052

BibTeX
@article{Xiao2026,
  author = {Xiao, Genfa and Chen, Yuanrong and Meng, Ying and Wang, Ziliang and Cai, Jiumei and Cao, Zuofeng and Zeng, Shixiu and Liang, Weihua and Yu, Yueling and Wang, Haobo and Nie, Lijun and Liu, Xiaoli and Liao, Yongling},
  title = {ADAMTS4 is a serum biomarker for pulmonary arterial hypertension associated with congenital heart disease},
  journal = {Frontiers in Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fmed.2026.1863052}
}
Kostenlos starten →